![Alliance News](https://static.lse.co.uk/images/news-logos/alliance-news-logo.png)
UK TRADING UPDATE SUMMARY: Venture Life Sees Order Boost For Sanitiser
UK TRADING UPDATE SUMMARY: Venture Life Sees Order Boost For Sanitiser
Read moreFri, 03rd Dec 2021 13:23
UK TRADING UPDATE SUMMARY: Venture Life Sees Order Boost For Sanitiser
Read moreUK TRADING UPDATE SUMMARY: Open Orphan Launches Covid Testing Service
Read moreUK TRADING UPDATE SUMMARY: Feedback And Tissue Regenix Secure CE Marks
Read moreUK TRADING UPDATE SUMMARY: New Trend Lifestyle Sees Extended Turmoil
Read moreHutchison China Gets US FDA Fast Track Status For Surufatinib
Read moreHutchison China Sees Loss Widen But Lays "Foundations" In 2019
Read moreUK Earnings, Trading Statements Calendar - Next 7 Days
Read moreBy Tamara Mathias, Roxanne Liu and Manojna MaddipatlaFeb 12 (Reuters) - The fast-spreading coronavirus is starting to disrupt testing of experimental medicines in China, posing a threat to plans by global drugmakers that have invested billions of ...
Read more(Sharecast News) - Hutchison China MediTech, trading as Chi-Med, announced the availability of updated results from the phase 2 'CALYPSO' study of the savolitinib and 'Imfinzi' (durvalumab) combination in a cohort of patients with metastatic papillary renal cell carcinoma (PRCC) on Monday.
Read moreHutchison China Prices USD110 Million American Depositary Share Offer
Read moreHutchison China Plans USD110 Million American Depositary Share Offer
Read more(Sharecast News) - Hutchison China MediTech, trading as Chi-Med, announced on Friday that the independent data monitoring committee of the phase 3 pivotal study of surufatinib in advanced neuroendocrine tumours - pancreatic (SANET-p) has completed a pre-planned interim analysis.
Read moreHutchinson China Reports Early Success Of Surufatinib Phase III Study
Read moreHutchison China Starts Phase II Study For Cancer Treatment In China
Read more(Sharecast News) - Hutchison China MediTech announced on Friday that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has granted 'Priority Review' status to its new drug application for 'surufatinib', for the treatment of patients with advanced non-pancreatic neuroendocrine tumours.
Read more